This appropriation is intended to cover expenditure on the evaluation of designated orphan medicinal products on specialised studies and consultations contracted out to highly qualified experts (individuals or firms) if the Agency does not have suitable staff available to carry out such studies, as provided for in Article 53(3) of Council Regulation (EEC) No 2309/93 or Article 62(3) of European Parliament and Council Regulation (EC) No 726/2004 as appropriate.